News Release

2012

2012.03.19
TAKARA BIO INC.

Takara Bio Submitted an Investigational New Drug (IND) Application for HIV-1 Gene Therapy to the Food and Drug Administration (FDA)

March 19, 2012---- Takara Bio Inc. announced today that Takara Bio and its collaborator, University of Pennsylvania have jointly submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated March 17, 2012 in order to conduct a ribonuclease MazF based gene therapy phase I clinical trial for HIV-1 infection disease in the United States.

Takara Bio has been developing a novel retroviral technology for HIV-1 gene therapy, in which MazF, an endoribonuclease from Escherichia coli, confers resistance to a broad-spectrum of HIV-1 strains on CD4+ T cells. We have demonstrated that human T cells transduced with MazF can significantly inhibit the replication of HIV-1 in vitro without affecting cellular functions. We have also demonstrated a promising result that MazF is similarly effective against multi-drug resistant HIV-1 clinical isolates in collaboration with Kagoshima University. Furthermore, we have confirmed the safety of the MazF-transduced T cells in vivo animal experiments using macaques in collaboration with Tsukuba Primate Research Center of National Institute of Biomedical Innovation (Tsukuba, Japan).

Takara Bio has entered into a collaboration research agreement with University of Pennsylvania on March 11, 2010 and has been pursuing an IND application with a group headed by Carl H. June, MD, Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine, and has now completed a series of preparations such as; preclinical translational studies, GMP manufacturing of MazF retroviral vector, GMP manufacturing of MazF-transduced CD4+ T cells, and has finally submitted the documents for the IND application. After IND review by the FDA, followed by protocol reviews by academic/additional regulatory committees including IRB, Takara Bio will initiate a phase I clinical trial in the U.S.. The study will be conducted by Dr. Jeffrey Jacobson, Professor of Medicine, Microbiology and Immunology, and Chief of the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine.


[Outline of planned clinical trial]

Sponsors:Takara Bio Inc./University of Pennsylvania
Trial subjects:HIV-1 positive adult men and women
Objectives:To evaluate the safety, tolerability and immunogenicity of autologous CD4+ T cells transduced with a retroviral vector expressing the MazF endoribonuclease in patients with HIV-1
Number of subjects:12 subjects
Trial period :3 years
Location of trial:Drexel University College of Medicine,Pennsylvania, U.S.A.
Principal Investigator:Jeffrey Jacobson, MD


[ About Takara Bio Inc. ]

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.



For more information:Corporate Communications, Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp

This article is translated from press release in Japanese for your convenience.



Forward-Looking Statements

Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, decline in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

return to top